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Activating signal cointegrator-2 (ASC-2), a coactivator of multiple
transcription factors that include retinoic acid receptor (RAR),
associates with histone H3-K4 methyltranferases (H3K4MTs) MLL3
and MLL4 in mixed-lineage leukemia. Here, we show that mice
expressing a SET domain mutant of MLL3 share phenotypes with
isogenic ASC2/ mice and that expression and H3-K4 trimethyla-
tion of RAR target gene RAR-2 are impaired in ASC-2-null mouse
embryo fibroblasts (MEFs) or in MEFs expressing siRNAs against
both MLL3 and MLL4. We also show that MLL3 and MLL4 are found
in distinct ASC-2-containing complexes rather than in a common
ASC-2 complex, and they are recruited to RAR-2 by ASC-2. In
contrast, RAR-2 expression is intact in MEFs devoid of menin, a
component of MLL1 and MLL2 H3K4MT complexes. These results
suggest that ASC-2 confers target gene specificity to MLL3 and
MLL4 H3K4MT complexes and that recruitment of H3K4MTs to
their target genes generally involves interactions between integral
components of H3K4MT complexes and transcription factors.
mixed-lineage leukemia (MLL)  retinoic acid receptor  transcription
Nuclear receptors (NRs) bind hormone response elements intarget genes and regulate transcriptional initiation in a ligand-
dependent manner (1). During ligand binding, the conserved
C-terminal activation function 2 domain undergoes a structural
change (1) that is recognized by an -helical LXXLL motif (NR
box) in transcriptional coactivators (2). Activating signal cointegra-
tor-2 (ASC-2; also named AIB3, TRBP, TRAP250, NRC, and
PRIP), a coactivator of many NRs and other transcription factors,
contains twoNRboxes (3). NR box 1 bindsmultiple NRs, including
retinoic acid receptor (RAR), whereasNRbox 2 interacts with liver
X receptors. The physiological importance of ASC-2 as a key
coactivator of these NRs and the pivotal roles of both NR boxes in
this context have been proposed from recent studies with various
ASC-2 mouse models (3).
In HeLa nuclei, ASC-2 resides in a steady-state complex
[ASC-2 complex (ASCOM)] (4) that contains retinoblastoma-
binding protein RbBP5, -tubulins, and trithorax group pro-
teins Ash2L, MLL4-1ALR-1, MLL4-2ALR-2, and MLL3
HALR (the paralog of MLL4ARL).†† MLL4-1 and MLL4-2
(collectively MLL4s) are encoded by the same gene, and they
differ only at their N termini (4). The C termini of MLL3 and
MLL4s contain a SET domain (5) with an intrinsic histone
lysine-specific methyltransferase activity. Indeed, recombinant
MLL3 and MLL4 SET domains and partially immunopurified
ASCOM exhibit weak but specific histone H3-K4 methyltrans-
ferase (H3K4MT) activity in vitro (4).
H3-K4 methylation, an evolutionarily conserved mark linked
to transcriptionally active chromatin, has been proposed to
counter the generally repressive chromatin environment im-
posed by H3-K9K27 methylation in higher eukaryotes (6). In
particular, H3-K4 trimethylation is associated with promoters
and early transcribed regions of active genes (7, 8). H3K4MTs
include yeast Set1 (ySet1), hSet1, MLL1, MLL2, and MLL3 and
MLL4s, as well as Ash1 and Set79 (4, 6, 9–12). Mixed-lineage
leukemias (MLLs), hSet1, and ySet1 form similar complexes,
called Set1-like complexes (6). Interestingly, H3-K4 methylation
has been linked to other chromatin-modifiers such as histone
acetyltransferases and chromatin remodelers (13–17). In yeast,
H3-K4 methylation by ySet1 is downstream from histone H2B
ubiquitination, and it requires Paf1 and other transcription
elongation factors (6, 18).
Transactivation of RAR-2, a well characterized RAR target
gene, involves ligand-dependent recruitment of ASCOM to the
RAR-2 promoter in vivo, likely through the NR box 1 of ASC-2
(4). Thus, an ASC-2 fragment with an intact NR box 1 (DN1),
but not one with a mutated LXXLL that disables NR interac-
tions (DN1m), blocks RAR transactivation in transient co-
transfections, abolishes the ligand-dependent recruitment of
ASC-2 and other ASCOM components (Ash2L and MLL4s) to
the RAR-2 promoter, and inhibits retinoid-induced H3-K4
trimethylation at RAR-2 (4). These results suggest that direct
ligand-dependent interactions between ASC-2 NR boxes and
NRs (3) allow MLL3 and MLL4s in ASCOM to affect H3-K4
trimethylation and expression of NR target genes. However, this
model has two prominent issues that remain to be addressed.
First, the NR box 1-containing DN1 fragment could block not
only ASC-2 but also the function of other essential NR box-
containing coactivators (19, 20). Second, the weak in vitro
H3K4MT activity of ASCOM (4) and the presence of multiple
H3K4MTs in mammalian cells (4, 6, 9–12) question the direct
role of MLL3 or MLL4s in retinoid-induced RAR-2 H3-K4
trimethylation (4).
Our original purification of ASCOM revealed the presence of
multiple H3K4MTs (4). Here, we show that ASCOM represents
a pool of similar complexes and that each complex contains a
single H3K4MT (i.e., MLL4-1, MLL4-2, or MLL3) and an
evolutionarily conserved WDR5RbBP5Ash2L core complex
(21). We also demonstrate that ASC-2 is a key adaptor for
RAR-dependent recruitment of MLL3 and MLL4s and their
H3K4MT activities to RAR-2, whereas RAR-2 expression is
intact in mouse embryo fibroblasts (MEFs) devoid of menin, an
integral component of MLL1 and MLL2 H3K4MT complexes.
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Thus, ASC-2 confers target gene specificity to ASCOM. Re-
cruitment of other Set1-like H3K4MTs to their target genes may
also involve direct interactions between bona fide components of
Set1-like complexes and DNA-binding transcription factors.
Results
Similar Phenotypes of MLL3 and ASC-2 Mutant Mice. To elucidate
the physiological role of ASCOM, we decided to establish
mouse models for MLL3 and MLL4. MLL3 contains 4,025 aa,
and, in an effort to preserve the overall structural integrity of
its interactions with other components in ASCOM, we de-
signed a targeting vector for an in-frame deletion of two exons
that encode a 61-aa catalytic core region in the MLL3 SET
domain (Fig. 1A). 129SVJ embryonic stem cell clones con-
taining the correctly integrated construct were identified by
Southern blot assays (Fig. 1B), and they were used to generate
chimeric mice. Heterozygous MLL3/ mice, created by cross-
ing with protamine-Cre animals (22), were mated to generate
MLL3/ mice, as confirmed by genomic DNA (Fig. 1C) and
mRNA (Fig. 1D) analyses.
Genotyping of 87 P14 pups from intercrosses ofMLL3/mice
revealed that the number ofMLL3/ mice is significantly lower
than the expected Mendelian ratio (Fig. 2A), suggesting a
reduced survival of homozygous mice. Indeed, we observed
occasional MLL3/ embryos undergoing necrosis (Fig. 2B).
Thus, a homozygous deletion of exons 25 and 26 appears to result
in partial embryonic lethality.
ASC-2/ mice die at embryonic day (E) 9.5–13.5 (3). Al-
thoughMLL3/mice exhibited no apparent phenotypic defects,
MLL3/ mice showed at least three phenotypes strikingly
similar to those recently described for isogenic ASC-2/ mice
(23). First,MLL3/mice were retarded in eye opening (Fig. 2C)
and stunted in their overall growth (Fig. 2D) relative to wild-type
littermates. They weighed 30–40% less at birth, and although
they gained on wild-type littermates with age, they remained
20% smaller through adulthood (Fig. 2E). Second, in a
comparison of isolated E12.5 MEFs,MLL3/MEFs doubled at
approximately half the rate of wild-type MEFs (Fig. 2F). Sim-
ilarly, HEK293 cells expressing siRNA for ASC-2, MLL3, or
MLL4s also showed decreased cell proliferation (data not
shown). Finally, MLL3/ females were infertile to hypofertile,
whereas MLL3/ males were slightly hypofertile (data not
shown). These similarities with isogenic ASC-2/ mice (23)
provide genetic evidence for complex formation between MLL3
and ASC-2. The detailed analyses of fertility, fat, and renal
phenotypes of MLL3/ mice will be reported elsewhere.
The phenotypes ofMLL3/ mice are the result of deletion of
the catalytic region of the MLL3 SET domain because this
mutation does not significantly affect the stability of mutant
MLL3, the mRNA levels of mutant MLL3 and wild-type ASC-2
and MLL4s, or the incorporation of mutant MLL3 protein into
ASCOM. Thus, immunoblots from three independent experi-
ments revealed comparable amounts of MLL3 and ASC-2
proteins in wild-type and MLL3/MEFs (Fig. 3A and data not
shown). Comparable amounts of ASC-2, MLL3, and MLL4
proteins were found at organism levels in wild-type andMLL3/
mice (data not shown). Consistently, quantitative PCR (Q-PCR)
analyses revealed no significant differences in the mRNA levels
of ASC-2, MLL3, and MLL4s between wild-type and MLL3/
MEFs (Fig. 3B). Mutant MLL3 protein is incorporated into the
ASC-2 complex because ASC-2 antibody coimmunoprecipitated
mutant MLL3 protein from MLL3/ MEFs as readily as wild-
type MLL3 from wild-type MEFs (Fig. 3C).
Fig. 1. Generation of MLL3/ mice. (A) Wild-type (wt) and targeted MLL3
loci are shown schematically with loxP sites (filled triangles) and the neomycin
resistance gene flanked by two Frt sites. Exons 25 and 26 encode 61 aa that
include the RYINHS motif, which contributes to the catalytic core region of the
SET domain. The genomic positions of the Southern blotting probes and PCR
primers are indicated. (B) Southern blot analyses of recombinedMLL3 locus. A
representative clone (clone 12) generates targeted locus-specific bands of 5.5
and 4.4 kb from BglII and NcoI restriction digestions, respectively. (C) In
genomic PCR, primers ab generate a 650-bp band for the targetedMLL3 locus
and a 2,100-bp band for the wild-type MLL3 locus. Primers cd generate a
350-bp band only from the wild-type MLL3 locus. (D) In RT-PCR, primers ef
generate a 265-bp band for both wild-type and targeted MLL3 mRNAs,
whereas primers gh generate a 356-bp band for wild-type MLL3 mRNAs and
a 172-bp band for targeted MLL3 mRNAs. The asterisk indicates primers.
Fig. 2. Similarity of MLL3 and ASC-2 at the genetic level. (A) Genotypes of 87
P14. (B) Representative picture of a dying E13.5 MLL3/ embryo (arrow). (C)
Representative 2-week-old MLL3/ mouse, retarded in eye opening (arrow),
and its wild-type littermate. (D) Representative 4-week-old MLL3/ mouse,
with stunted growth, shown with its wild-type littermate. (E) Body weights of
MLL3/ (n  3) mice and their wild-type littermates (n  4) over a 60-day
period. (F) Ten thousand wild-type and MLL3/ MEFs were seeded in 9-cm2
wells, and the cells were harvested and counted each day for 6 days. A
representative result is shown.
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ASC-2 as a Key Adaptor for RAR-Mediated Recruitment of MLL3 and
MLL4s. To explore the roles of MLL3 and its SET domain in NR
transactivation, we focused on RAR and its target gene RAR-2.
We isolated E9.5 MEFs from wild-type,MLL3/, and ASC-2/
mice. Surprisingly, MLL3/ MEFs fully supported RAR trans-
activation, as evidenced by Q-PCR analysis of 9-cis-RA-induced
levels of RAR-2 mRNAs (Fig. 3D). In contrast, ASC-2/
MEFs failed to support RAR transactivation (Fig. 3D). Sup-
porting the specificity ofASC-2/MEFs, reexpression of ASC-2
in these cells restored RAR transactivation (Fig. 3E). These
results demonstrate that ASC-2, but not MLL3, is essential for
RAR transactivation in MEFs.
Although several H3K4MTs were originally shown to interact
with ASC-2 (4), a further analysis with antibodies specific for
MLL3 and MLL4s (4) indicated that these H3K4MTs form
distinct ASC2-containing complexes. Thus, MLL3 antibody co-
immunoprecipitated ASC-2 and MLL3 but not MLL4, whereas
MLL4 antibody coimmunoprecipitated ASC-2 and MLL4 but
not MLL3 from HeLa nuclear extracts (Fig. 3F). Similarly,
MLL4-1-specific antibody coimmunoprecipitated ASC-2 and
MLL4-1 but not MLL3; and MLL3 antibody coimmunoprecipi-
tated no MLL4-1 (data not shown). These results, along with the
presence of a single H3K4MT in all of the known Set1-like
complexes, suggest that ASCOM is likely a pool of three
complexes, namely, ASCOM(MLL4-1), ASCOM(MLL4-2), and
ASCOM(MLL3).
The presence of several distinct ASCOMs and the essentiality
of ASC-2 but not MLL3 for RAR transactivation in MEFs (Fig.
3D) suggested the possibility of a functional redundancy of
ASCOMs for RAR transactivation. To test this possibility, we
examined a series of different siRNAs against MLL3 and
MLL4s. The selected siRNAs were highly specific when tran-
siently expressed in HEK293 cells, as demonstrated by the
observation that a given siRNA affected its own expression but
neither the mRNA levels nor the protein levels of other key
components of ASCOM (Fig. 4A and data not shown). Consis-
tent with the results fromMLL3/MEFs (Fig. 3D), each siRNA
alone did not affect 9-cis-RA-dependent expression of RAR-2
mRNAs in HEK293 cells (Fig. 4B). However, cotransfection of
both siRNAs resulted in an 50% reduction in the 9-cis-RA-
induced level of RAR-2 mRNAs (Fig. 4B). Transfection effi-
ciencies for single siRNA transfections were 70–85%, and, as
measured by Q-PCR, both MLL3 and MLL4 mRNA levels were
simultaneously down-regulated in doubly transfected cells (data
not shown). These results suggest that MLL3 and MLL4s both
function with RAR and that the intact RAR transactivation in
MLL3/ MEFs (Fig. 3D) likely results from the function of
ASCOM(MLL4s).
To demonstrate further the functional redundancy of MLL3
andMLL4 complexes, we tested siRNAs directed against other
shared components of ASCOMs. WDR5 is a common com-
ponent of ySet1, MLL1, MLL2, and hSet1 complexes; it
Fig. 3. MLL3/ MEFs support RAR transactivation. (A) Nuclear extracts of
E12.5 MEFs from wild-type and MLL3/ mice were immunoblotted (IB) with
MLL3, ASC-2, and -actin antibodies as well as MLL3 antibody preincubated
with recombinant MLL3 protein or BSA (data not shown). (B) In Q-PCR, the
transcript levels of ASC-2, MLL3, and MLL4s were measured in E12.5 wild-type
and MLL3/ MEFs. (C) Immunoprecipitation (IP) of nuclear extracts of E12.5
wild-type and MLL3/ MEFs by IgG and ASC-2 antibody was followed by
immunoblotting with MLL3 antibody. (D) E9.5 wild-type (wt), MLL3/, and
ASC-2/ MEFs were treated with vehicle or 0.1 M 9-cis-retinoic acid (RA) for
12 h, and RAR-2 transcript levels were determined by Q-PCR. (E) E9.5 wild-
type and ASC-2/ MEFs were transfected with 2-RARE-Luc reporter and an
increasing amount of ASC-2 expression vector; then they were treated with
vehicle or 0.1M 9-cis-RA for 12 h and tested for luciferase activity. (F) Nuclear
extracts of HeLa cells were subjected to immunoprecipitations with IgG and
antibodies against MLL4s and MLL3 followed by immunoblotting with the
indicated antibodies (4).
Fig. 4. ASC-2 is a key adaptor for RAR-dependent recruitment of MLL3 and
MLL4s. (A) HEK293 cells were transfected with siRNA against MLL3 or MLL4s,
along with CMV-GFP. These cells were immunostained for MLL3, MLL4s, and
ASC-2, 3 days posttransfection. GFP-positive cells (i.e., transfected cells; ar-
rows) were monitored for the expression of MLL3, MLL4s, and ASC-2. (B)
HEK293 cells were transfected with control siRNA, siRNA against MLL3 or
MLL4s, or siRNAs for both MLL3 and MLL4s. Two days posttransfection, cells
were treated with vehicle or 0.1 M 9-cis-RA (9-RA) for 12 h, and they were
then tested for RAR-2 transcript levels by Q-PCR. (C) Nuclear extracts of HeLa
cells were subjected to immunoprecipitations (IP) with IgG and ASC-2 anti-
body followed by immunoblotting with ASC-2 and WDR5 antibodies. (D)
HEK293 cells were transfected with control (con) siRNA or siRNA against WDR5
or RbBP5. Two days posttransfection, cells were treated with vehicle or 0.1M
9-cis-RA for 12 h and tested for RAR-2 and GAPDH (control; data not shown)
transcripts by Q-PCR. (E) Immortalized cell lines from wild-type (wt) and
ASC-2/MEFs were treated with 0.1 M 9-cis-RA for 0–45 min and subjected
to ChIPs with antibodies against MLL3 and MLL4s.
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associates with histone H3-K4-dimethylated nucleosomes (24),
and it plays a key role in presenting the H3 substrate to the
MLL1 H3K4MT complex (21). Because we failed to identify all
ASCOM components in our original purification (4), we tested
whether WDR5 is included in ASCOM. Immunoprecipitation
of HeLa nuclear extracts by ASC-2 antibody, followed by
immunoblotting with WDR5 antibody, revealed that WDR5 is
indeed associated with ASC-2 (Fig. 4C). Thus, the core
components (WDR5, RbBP5, and Ash2L) of H3K4MT com-
plexes are conserved in ASCOM. Taking advantage of the key
regulatory roles of these core components in H3K4MT activ-
ity, we performed experiments with siRNA directed against
WDR5 or RbBP5. By using Q-PCR, we found that RAR-2
mRNAs are significantly decreased after 9-cis-RA induction in
HEK293 cells treated with RbBP5 or WDR5 siRNA compared
with control siRNA-treated HEK293 cells (Fig. 4D). These
siRNAs did not affect the level of GAPDH, whose expression
is RA-independent (data not shown). Thus, RAR transacti-
vation of RAR-2 should involve H3K4MT complex(es) con-
taining the core WDR5RbBP5Ash2L subcomplex but not
other complexes that lack this subcomplex (9–12). These
results, along with those obtained with ASC-2/ MEFs (Fig.
3D) and cells expressing MLL3 and MLL4 siRNAs (Fig. 4B),
suggest that ASCOMs provide the primary H3K4MTs respon-
sible for RAR transactivation of RAR-2.
Next, we directly tested the proposed adaptor role of ASC-2
in recruiting MLL3 and MLL4s to promoter-bound RAR.
Chromatin immunoprecipitation (ChIP) assays revealed that
both MLL3 and MLL4s are recruited in a ligand-dependent
manner to the RAR-2 promoter in wild-type MEFs (Fig. 4E).
Remarkably, their recruitment to RAR-2 was abolished in
immortalized cell lines derived from ASC-2/MEFs (Fig. 4E).
These results demonstrate that ASC-2 is an essential component
for recruiting MLL3 and MLL4s to RAR, validating our previ-
ous results with DN1 (4). This experimental evidence shows that
a bona fide subunit of H3K4MT complexes acts as a direct
adaptor to link these complexes to a DNA-binding transcription
factor.
H3-K4 Trimethylation of RAR-2 Requires ASC-2 and MLL3 or MLL4s.
The above results lead to a model in which RAR transactivation
requires MLL3 or MLL4s and ASC-2 functions as a key adaptor
for RAR-mediated recruitment of MLL3 and MLL4s. The
requirement for MLL3 or MLL4s likely reflects their essential
function to direct H3-K4 trimethylation of RAR target genes. To
test this model, we carried out ChIP assays using E9.5 MEFs
from wild-type, MLL3/, and ASC-2/ mice, and we specifi-
cally examined the histone-modification status of the RAR-2
promoter. In wild-type MEFs, histone H3-K4 trimethylation as
well as H3 and H4 acetylations were induced during 9-cis-RA
treatment (Fig. 5A). Similar modifications were also observed in
MLL3/MEFs (Fig. 5A). In contrast, H3-K4 trimethylation was
abolished in ASC-2/ MEFs compared with wild-type and
MLL3/MEFs (Fig. 5A). These results argue that ASC-2 targets
H3-K4 trimethylation activity mediated by both MLL3 and
MLL4s to RAR-2 (Fig. 4E). To test this idea directly, we
cotransfected HepG2 cells with siRNAs against MLL3 and
MLL4s (Fig. 4A). Indeed, 9-cis-RA-induced H3-K4 trimethyla-
tion ofRAR-2was significantly impaired in these cells (Fig. 5B).
Similar results were obtained with HEK293 cells (data not
shown). These results suggest that ASC-2 is a key adaptor for
RAR in mediating recruitment of MLL3 and MLL4s to RAR-2
and that MLL3 and MLL4s in turn methylate RAR-2 H3-K4
residues. Interestingly, H3 acetylation was also ablated, and H4
acetylation decreased in ASC-2/ MEFs (Fig. 5A), suggesting
cooperativity between ASCOM and H3H4 acetylation during
RAR transactivation.
We also tested whether 9-cis-RA-induced H3-K4 trimethyla-
tion of RAR-2 involves the core WDR5RbBP5Ash2L sub-
complex, which is important for regulating the H3K4MT activity
of Set1-like complexes (21). The decreased expression level of
RAR-2 mRNAs in cells treated with siRNA against WDR5 or
RbBP5 (Fig. 4D) correlated with significantly reduced H3-K4
trimethylation ofRAR-2 (Fig. 5C). These results, along with the
results observed with ASC-2/ MEFs (Fig. 5A) and cells
expressing MLL3 and MLL4s siRNAs (Fig. 5B), demonstrate
that ASCOM is the primary H3K4MT responsible for RA-
induced H3-K4 trimethylation of RAR-2.
ASC-2 Confers Target Gene Specificity to ASCOM. Menin is an
essential component of two mammalian Set1-like complexes,
namely, MLL1 andMLL2 complexes. Menin recently was shown
to function as a coactivator of estrogen receptor (ER) and to link
ER transactivation toH3-K4 trimethylation (25). Thus, we tested
whether menin acts as a redundant mediator of H3-K4 trim-
ethylation of RAR-2. Semiquantitative RT-PCR analyses re-
vealed that 9-cis-RA induced RAR-2 mRNAs in wild-type
cells, whereas it was inert in E9.5 ASC-2/MEFs (Fig. 5D Left).
Interestingly, 9-cis-RA fully induced RAR-2 mRNAs in im-
mortalized cell lines derived from menin/ MEFs (Fig. 5D
Right). These results demonstrate that RAR transactivation
requires ASCOM and that highly homologous, menin-associated
MLL1 and MLL2 H3K4MT complexes cannot replace ASCOM.
Importantly, these results suggest that unique components of
H3K4MT complexes may serve as key specificity determinants to
direct different H3K4MT complexes to specific transcription
factors. Thus, ASC-2 targets ASCOMs to RAR, whereas menin
may possibly tether MLL1 or MLL2 complexes to ER (25).
Discussion
The present study significantly extends our earlier report (4) of
a complex (ASCOM) containing MLL3, MLL4s, and ASC-2 by
Fig. 5. RAR-2 H3-K4 trimethylation requires ASC-2 and MLL3 or MLL4. (A)
E9.5 wild-type (wt),MLL3/, andASC-2/MEFs were subjected to ChIP assays
for H3-K4 trimethylation and H3H4 acetylation during treatment with vehi-
cle or 0.1 M 9-cis-RA (9RA) for 2 h. (B) HepG2 cells transfected with control
(con) siRNA or siRNAs for both MLL4s and MLL3 were treated with vehicle or
0.1M 9-cis-RA for 2 h, 2 days posttransfection, and they were then subjected
to ChIPs for H3-K4 trimethylation. (C) HepG2 cells transfected with control
siRNA or siRNA for WDR5 or RbBP5 were treated with vehicle or 0.1 M
9-cis-RA for 2 h, 2 days posttransfection, and they were then subjected to ChIPs
for H3-K4 trimethylation of RAR-2. These siRNAs had no effect on H3-K4
trimethylation of GAPDH (data not shown). (D) E9.5 wild-type and ASC-2/
MEFs, as well as immortalized cell lines derived from wild-type and menin/
MEFs, were treated with vehicle or 0.1 M 9-cis-RA for 12 h, and 9-cis-RA
induction of RAR-2 mRNAs was measured by RT-PCR.
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showing that MLL3 and MLL4s exist with ASC-2 in distinct
complexes with at least partially redundant functions. We dem-
onstrate the highly specific and essential roles of MLL3 and
MLL4s in ASC-2-dependent transactivation of RAR-2, an
essential function of ASC-2 in recruiting MLL3 and MLL4s
to RAR-2 in a retinoid-dependent manner, and a key role
for MLL3- andor MLL4-dependent H3-K4 trimethylation in
transcriptional activation of RAR-2. Collectively, we
propose a model for the function of ASCOM(MLL3) and
ASCOM(MLL4s) in RAR transactivation that entails (i) inde-
pendent recruitment of an ASCOM complex to RAR by retin-
oid-dependent interactions between RAR and NR box 1 of
ASC-2; (ii) stabilization of the binding of ASCOMs to the H3 tail
by WDR5 in theWDR5RbBP5Ash2L subcomplex (21, 24); and
(iii) MLL3- and MLL4-mediated H3-K4 trimethylation of the
promoter region bound by RAR.
The SET Domain Is Pivotal for ASCOMMLL3 Function. The successful
establishment of MLL3/ mice is a major advancement in under-
standing the physiological function of ASCOMs. Although the
MLL3 SET domain deletion mutant is expressed at a normal level
and incorporated into the ASC-2 complex (Fig. 3 A–C), the
observation that some MLL3 functions are impaired suggests
important roles for the SET domain and its H3K4MT activity in
MLL3 function. The similar phenotypes of MLL3/ and isogenic
ASC-2/ mice suggest genetic interactions between the two pro-
teins in vivo. The more severe phenotype of ASC-2/ (3) can be
partially explained by the redundant functions of MLL3 and
MLL4s. Because ASC-2 is a common component of both MLL3
and MLL4 complexes, the ASC-2-null phenotypes are likely the
sum of MLL3- and MLL4-deficient phenotypes rather than just an
MLL3-null phenotype. In addition, because MLL3 is a very large
protein that contains multiple domains, some of its functions are
likely SET domain-independent. However, although all ASC-2
proteins appeared to be associated with MLL3 and MLL4 com-
plexes in our original purification (4), it has not yet been tested
whether allMLL3 andMLL4s are associated with ASC-2. Thus, we
cannot exclude the possibility that MLL3 and MLL4s have some
ASC-2-independent functions.
ASC-2 Confers Specificity to ASCOMs. The Set1-like complexes
contain unique components such as menin and host cell factors
inMLL1 andMLL2 (6) andASC-2 inMLL3 andMLL4s (4). The
existence of unique components in different H3K4MT com-
plexes argues for specific functions. Indeed, several observations
suggest specific roles for different H3K4MTs in transcription
regulation. Thus, MLL2 appears to be important for expression
of the HOX B gene cluster but not for expression of the HOX A
cluster (26), whereas HOX a9 and HOX c8 are exclusive MLL1
targets relative to other Set1-like H3K4MTs (27, 28). Although
the mechanisms underlying the specificity of the different Set1-
like H3K4MTs remain to be understood fully, the unique
components in different H3K4MT complexes (including
H3K4MTs themselves; see below) may confer specificity. Thus,
as demonstrated in this work, the unique integral component of
MLL3 and MLL4 complexes, ASC-2, is essential for RAR-
dependent transactivation, and RAR-2 expression and H3-K4
trimethylation are impaired inASC2/ cells but not inmenin/
cells. These results clearly demonstrate that RAR-2 is a specific
target for MLL3 and MLL4s but not for MLL1 and MLL2. This
specificity is likely achieved through the previously demon-
strated physical interactions between RAR and ASC-2 (3). In
further support of this notion, the MLL3 and MLL4 complexes,
which share ASC-2, demonstrate redundant functions for RAR
transactivation. Because ASC-2 is required for transactivation by
other NRs (3), it is likely that MLL3 andor MLL4s are directly
involved in their transactivation functions.
In addition to ASC-2, other notable components of ASCOM
are the catalytic subunits (MLL3 and MLL4s) themselves. MLL
family H3K4MTs are consistently large proteins with a highly
conserved C-terminal SET domain and highly divergent N-
terminal domains. Although MLL3 and MLL4s share a series of
conserved motifs that include the SET domain, their overall
homology is 30%. It will be important to determine whether
MLL3 and MLL4s have unique target genes in addition to
common targets such as RAR-2. Interestingly, MLL4-1, Ash2L,
RbBP5, andWDR5 were recently isolated fromDU4475 nuclear
extracts as ER-associated proteins. This estrogen-dependent
interaction involves the fifth and sixth LXXLLmotifs of MLL4-1
(29). As a result, this function of MLL4-1 is not redundant with
MLL3, and MLL4-1 siRNA treatment alone impairs ER-
dependent transactivation (29).
Recruitment of H3K4MTs Through Interactions with DNA-Binding
Transcription Factors. We have demonstrated here that ASC-2
tethers ASCOMs to RAR-2 in a ligand-dependent manner and
that MLL3 and MLL4, in turn, carry out H3-K4 trimethylation.
The recruitment of ASCOMs is likely mediated by NR box 1 of
ASC-2 because a dominant-negative fragment of ASC-2 con-
taining NR box 1 (DN1) impairs their recruitment (4), thus
providing experimental evidence for recruitment of anH3K4MT
complex to a natural promoter through the interaction of an
integral component with a DNA-binding transcription factor. A
similar recruitment mechanism has been indicated for ER with
MLL4-1 (29) as well as for -catenin withMLL1 andMLL2 (30).
Direct interactions between DNA-binding transcription factors
and H3K4MTs are likely a general phenomenon. Indeed, an
interaction between p53 and the MLL1 complex leads to tran-
scription activation in vitro (13), which implicates more active
roles of H3K4MTs in transcription activation than is generally
assumed (see below).
Notably, this recruitment mechanism is distinct from what
has been proposed for the ySet1 complex (6, 18, 31, 32) and
from an in vitro transcription study (33). The latter study
postulated that the H3-K4 methylation is solely a consequence
of transcription activation and that H3K4MT recruitment
depends on transcription elongation factors such as RNA
polymerase II-associated factor (PAF) and FACT. However,
this model fails to explain several observations in higher
eukaryotes: first, H3-K4 trimethylation is enriched in pro-
moter regions; second, interactions of methylated H3-K4
andor H3K4MTs with chromatin modifiers involved in tran-
scription initiation, such as NURF (34) and p300 (35), occur
at the promoter; third, although direct interactions among
FACT, the PAF complex, and the H2B ubiquitination ma-
chinery have been documented, direct interactions of these
components with H3K4MTs are not yet established in mam-
malian cells (although Paf1 interacts with Set1 in yeast; ref.
36). Finally, several recent reports demonstrate that siRNA-
mediated knockdown of components of the H2B ubiquitina-
tion machinery does not affect H3-K4me1 andor H3-K4me2
at target genes, suggesting intact recruitment of H3K4MTs
(33, 37). Future studies on the regulation H3-K4 methylation,
especially through an evolutionarily conserved mechanism
involving the PAF complex and H2B ubiquitination will likely
reveal functional interactions between different chromatin
modifiers and their involvement in transcription regulation.
Materials and Methods
Generation of MLL3/ Mice. The targeting construct was electro-
porated into embryonic stem cells and G418-selected. Correctly
recombined clones were used to generate chimeric animals (38).
The neo-heterozygotes (MLL3/Neo) were bred to a protamine-
Cre transgenic mouse line (22) to generateMLL3/mice, which
were bred to produceMLL3/mice. The primer sequences used
for genomic PCR are available on request.
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RT-Q-PCR. Total RNA was isolated from cells after lysis in
TRIzol reagent according to the manufacturer’s protocol (In-
vitrogen Corp., Carlsbad, CA), and RT- and SYBR Green
Q-PCRs were performed as described in refs. 20 and 39. The
primer sequences are available on request.
ChIPs. Soluble chromatin was prepared and immunoprecipitated
with the indicated antibodies, as described in ref. 40. The final
DNA extractions were amplified by using pairs of primers that
encompass the RAR-responsive element in the RAR-2 pro-
moter (4).
RNA Interference. Double-stranded DNA fragments that con-
tained the selected RNAi sequences positioned downstream
from the human U6 RNA polymerase III promoter were gen-
erated by PCR by using the Silencer express kit (Ambion, Austin,
TX) according to the manufacturer’s instructions. The DNA
fragments were cloned into the pSec vector (Ambion). Cells were
transfected with pSec derivatives. Three days later, ASC-2,
MLL4, and MLL3 expression levels were determined by Q-PCR
(data not shown) and by immunostaining with the indicated
antibodies (Fig. 4A). The siRNA sequences are available on
request.
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